These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1342 related articles for article (PubMed ID: 32531712)

  • 1. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
    Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
    Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the prognosis of resected early-stage patients with non-small cell lung cancer: A meta-analysis.
    Cao W; Yu H; Zhu S; Lei X; Li T; Ren F; Zhou N; Tang Q; Zu L; Xu S
    Cancer Med; 2023 Mar; 12(6):7065-7076. PubMed ID: 36480232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
    Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
    BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N; Chang J; Liu P; Tian X; Yu J
    Front Immunol; 2024; 15():1400262. PubMed ID: 38915398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
    Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
    Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 15. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
    Platini H; Ferdinand E; Kohar K; Prayogo SA; Amirah S; Komariah M; Maulana S
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
    Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
    Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
    BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
    Tan Q; Liu S; Liang C; Han X; Shi Y
    Thorac Cancer; 2018 Oct; 9(10):1220-1230. PubMed ID: 30151899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Chen R; Hou X; Yang L; Zhao D
    Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.